Development of COVID-19 Antiviral Therapy Using Human iPSC-Derived Lung Organoids
Grant Award Details
Grant Type:
Grant Number:
DISC2-12170
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$250,000
Status:
Closed
Progress Reports
Reporting Period:
Year 1/NCE period
Grant Application Details
Application Title:
Development of COVID-19 Antiviral Therapy Using Human iPSC-Derived Lung Organoids
Public Abstract:
Research Objective
To develop a new therapy for COVID-19 using human iPSC-derived lung organoids that targets SARS-CoV-2 protease known as the virus’ “Achilles Heel”
Impact
Our work, if successful, will bring a class of new drugs directly targeting viral enzyme and open the door for future COVID therapies.
Major Proposed Activities
To develop a new therapy for COVID-19 using human iPSC-derived lung organoids that targets SARS-CoV-2 protease known as the virus’ “Achilles Heel”
Impact
Our work, if successful, will bring a class of new drugs directly targeting viral enzyme and open the door for future COVID therapies.
Major Proposed Activities
- Complete synthesis and testing of new inhibitors
- Optimize and validate the new compounds activities in lung cells and organoids
- Rapidly expand the efficacy of SARS-CoV-2 inhibitors in a large panel of lung organoids from African-American, Latino, and Caucasian men and women.
- ensure that any newly emerging therapy will be applicable to all patients regardless of gender and race.
Statement of Benefit to California:
The emergence of novel coronavirus SARS-CoV-2 and its associated disease, COVID-19, has presented an urgent global public health crisis. In California, more than 700,000 individuals have been infected leading ~13,000 deaths. Further, Californians are grappling with the economic impact due to job loss and business shutdowns. Finding a treatment for COVID-19 would have a huge impact on saving lives, preventing new infections, and helping people to return to normal activities of life.
Publications
- J Med Chem (2021): Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors. (PubMed: 34570513)
